Polo-like Kinases (PLKs) are a family of highly conserved serine/threonine protein kinases that are essential for a variety of biological functions, including cell division and mitosis checkpoint regulation. Five PLKs (PLK 1-5) play a variety of roles in DNA damage response, intra-S-phase and G2/M checkpoints, spindle formation, and centrosome dynamics in mammals.
PLKs are distinguished by their Polo-box domain, which mediates protein interactions. Depending on the biological context, they are also regulated by transcription, proteolysis, and phosphorylation. PLKs are now understood to function in differentiated cells and link cell division to developmental processes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V137856 | IIP0943 | 3040106-93-9 | IIP0943 is a selective PLK1 (polo-like kinase 1) inhibitor with an IC50 value of 5.1 nM against PLK1. |
|
V1578 | MLN0905 | 1228960-69-7 | MLN0905 (MLN-0905; MLN 0905) is a novel, potent and selective small-molecule inhibitor of polo-like kinase-1 (PLK1) with potential antineoplastic activity. |
|
V142089 | p53-Y220C/PLK1 modulator-1 | 3114732-99-6 | p53-Y220C/PLK1 modulator-1 is a dual modulator targeting both p53-Y220C and PLK1. |
|
V88743 | PLK1-IN-10 | 2991469-21-5 | PLK1-IN-10 (Compound 4Bb) is an orally available PLK1 PBD (polo-box domain) inhibitor. |
|
V142851 | PLK1-IN-11 | 73663-97-5 | PLK1-IN-11 is a PLK1 inhibitor with an IC50 of 1 μM. |
|
V142852 | PLK1-IN-12 | PLK1-IN-12 is a highly selective, orally effective PLK1 inhibitor with an IC50 value of 20 nM. | |
|
V142854 | PLK1-IN-14 | PLK1-IN-14 is a selective PLK1 inhibitor. | |
|
V142855 | PLK1-IN-15 | 3068529-37-0 | PLK1-IN-15 is a PLK1 inhibitor (IC50: 38.5 nM). |
|
V142856 | PLK1-IN-16 | 3068378-51-5 | PLK1-IN-16 is a selective Polo-like kinase 1 (PLK1) inhibitor with an IC50 value of 0.25 nM. |
|
V55106 | PLK1-IN-2 | 2640254-52-8 | PLK1-IN-2 is a PLK1 kinase inhibitor (antagonist) with IC50 of 0.384 μM. |
|
V55107 | PLK1-IN-5 | 1001343-34-5 | PLK1-IN-5 is a potent PLK1 inhibitor (antagonist) with IC50 < 500 nM. |
|
V75966 | PLK1-IN-7 | 2938910-96-2 | PLK1-IN-7 (compound 30e) is a potent inhibitor of PLK1 with IC50 of 0.66 nM. |
|
V85855 | PLK1-IN-8 | ||
|
V88746 | PLK1-IN-9 | 893772-67-3 | PLK1-IN-9 (Compound M2) is a polo-like kinase 1 (PLK1) inhibitor that inhibits PLK protein modified by peptide 1010pT, cdc25c, and PBIP with IC50 of 1.6, 0.8, and 1.4 μM, respectively. |
|
V142850 | PLK1/PRC1-IN-1 | 2991469-28-2 | PLK1/PRC1-IN-1 is an inhibitor of PLK1/PRC1 protein complex formation. |
|
V1580 | NMS-P937 (NMS1286937; Onvansertib) | 1034616-18-6 | NMS-P937 (also know as NMS-P937;NMS1286937;NMS-P-937; NMS-P 937; Onvansertib) is an orally bioavailable, potent, selective, small-molecule Polo-like Kinase 1 (PLK1) inhibitor with potential antitumor activity. |
|
V116561 | PLK2 Recombinant Human Active Protein Kinase | PLK2 belongs to the Polo-like kinase (PLK) family, which includes five mammalian members and plays a central role in the cell cycle and related events. | |
|
V55108 | PLK4-IN-1 | 1247001-12-2 | PLK4-IN-1 (Example A6) is an inhibitor (blocker/antagonist) of PLK4 with IC50 of ≤ 0.1 μM. |
|
V55109 | PLK4-IN-3 | 1247001-86-0 | PLK4-IN-3 is the absolute configuration of PLK4-IN-1. |
|
V84180 | PLK4-IN-4 | 2923999-01-1 |